莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300006 莱美药业

已收盘 11-22 15:00:00

{"stockData":{"symbol":"300006","market":"SZ","secType":"STK","nameCN":"莱美药业","latestPrice":4.58,"timestamp":1732258995000,"preClose":4.88,"halted":0,"volume":27414740,"delay":0,"floatShares":1056000000,"shares":1056000000,"eps":0.0182,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.3,"latestTime":"11-22 15:00:00","open":4.88,"high":4.89,"low":4.56,"amount":129000000,"amplitude":0.0676,"askPrice":4.59,"askSize":1763,"bidPrice":4.58,"bidSize":2301,"shortable":0,"etf":0,"ttmEps":0.0182,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":4.88,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":5.37,"lowLimit":4.39,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1055911205,"pbRate":2.51,"roa":"--","roe":"--","epsLYR":-0.0085,"committee":0.197349,"marketValue":4836000000,"floatMarketCap":4836000000,"peRate":251.648341,"changeRate":-0.0615,"turnoverRate":0.026,"status":1},"requestUrl":"/m/hq/s/300006/wiki","defaultTab":"wiki","newsList":[{"id":"2479471232","title":"中恒集团最新公告：控股子公司莱美药业获得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2479471232","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479471232?lang=zh_cn&edition=full","pubTime":"2024-10-29 18:30","pubTimestamp":1730197851,"startTime":"0","endTime":"0","summary":"中恒集团公告，控股子公司莱美药业近日收到国家药品监督管理局核准签发的艾司奥美拉唑镁肠溶胶囊（规格：20mg和40mg）和氨甲环酸氯化钠注射液（规格：100ml）《药品补充申请批准通知书》。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900034742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0015","BK0012","BK0070","BK0239","BK0077","600252","300006","BK0188","BK0028"],"gpt_icon":0},{"id":"2479223014","title":"莱美药业最新公告：获得尼莫地平注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2479223014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479223014?lang=zh_cn&edition=full","pubTime":"2024-10-29 16:52","pubTimestamp":1730191930,"startTime":"0","endTime":"0","summary":"莱美药业公告，公司收到国家药品监督管理局核准签发的尼莫地平注射液（规格：50ml：10mg）《药品注册证书》。尼莫地平注射液主要用于预防和治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛引起的缺血性神经损伤。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900028755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"gpt_icon":0},{"id":"2477351666","title":"莱美药业：10月23日高管赖文增持股份合计2500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2477351666","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477351666?lang=zh_cn&edition=full","pubTime":"2024-10-24 21:01","pubTimestamp":1729774871,"startTime":"0","endTime":"0","summary":"证券之星消息，根据10月24日市场公开信息、上市公司公告及交易所披露数据整理，莱美药业（300006）最新董监高及相关人员股份变动情况：2024年10月23日公司高管赖文共增持公司股份2500.0股，占公司总股本为0.0002%。变动期间公司股价下跌0.99%，10月23日当日收盘报4.0元。莱美药业近半年内的董监高及核心技术人员增减持详情如下：莱美药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1212.79万，融资余额增加；融券净流入2300.0，融券余额增加。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400036745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300006","BK0070"],"gpt_icon":0},{"id":"2477159950","title":"莱美药业（300006）2024年三季报简析：亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2477159950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477159950?lang=zh_cn&edition=full","pubTime":"2024-10-24 06:05","pubTimestamp":1729721146,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期莱美药业发布2024年三季报。根据财报显示，莱美药业亏损收窄。截至本报告期末，公司营业总收入6.06亿元，同比下降6.07%，归母净利润-2641.67万元，同比上升51.54%。本次财报公布的各项数据指标表现一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400004711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"gpt_icon":0},{"id":"2477363934","title":"图解莱美药业三季报：第三季度单季净利润同比减5972.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477363934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477363934?lang=zh_cn&edition=full","pubTime":"2024-10-23 00:32","pubTimestamp":1729614729,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业2024年三季报显示，公司主营收入6.06亿元，同比下降6.07%；归母净利润-2641.67万元，同比上升51.54%；扣非净利润-5564.32万元，同比下降99.94%；其中2024年第三季度，公司单季度主营收入2.24亿元，同比上升17.29%；单季度归母净利润-2774.49万元，同比下降5972.02%；单季度扣非净利润-2807.6万元，同比下降225.92%；负债率30.6%，投资收益-1772.25万元，财务费用-1398.73万元，毛利率63.4%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300000177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006"],"gpt_icon":0},{"id":"2477388881","title":"莱美药业最新公告：前三季度净利润亏损2641.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477388881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477388881?lang=zh_cn&edition=full","pubTime":"2024-10-22 17:20","pubTimestamp":1729588834,"startTime":"0","endTime":"0","summary":"莱美药业发布2024年第三季度报告，公司前三季度实现营业收入6.06亿元，同比下降6.07%；归属于上市公司股东的净利润亏损2641.67万元。第三季度实现营业收入2.24亿元，同比增长17.29%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200028841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006"],"gpt_icon":0},{"id":"2477807187","title":"莱美药业(300006.SZ)发布前三季度业绩，净亏损2641.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477807187","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477807187?lang=zh_cn&edition=full","pubTime":"2024-10-22 16:59","pubTimestamp":1729587571,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)发布2024年第三季度报告，公司前三季度营业收入6.06亿元，同比下降6.07%;归属于上市公司股东的净亏损2641.67万元;归属于上市公司股东的扣除非经常性损益的净亏损5564.32万元;基本每股亏损0.025元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300006","BK0070"],"gpt_icon":0},{"id":"2475527371","title":"莱美药业：持股5%以上股东邱宇所持0.72%股份被动减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2475527371","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475527371?lang=zh_cn&edition=full","pubTime":"2024-10-15 10:38","pubTimestamp":1728959893,"startTime":"0","endTime":"0","summary":"中国财富通10月15日 - 莱美药业（300006）公告称，持股5%以上股东邱宇因与国海证券开展质押式证券回购业务相关债务逾期，国海证券拟依据广西壮族自治区南宁市青秀区人民法院出具的《协助执行通知书》，将通过集中竞价方式继续处置邱宇持有的755.40万股公司股份，占公司总股本的0.72%。本次减持计划自本公告披露之日起15个交易日（2024年11月5日）后的3个月内进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=q%2F%2FNhjh9XDY%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300006","BK0070"],"gpt_icon":0},{"id":"2475367848","title":"莱美药业(300006.SZ)股东邱宇所持755.40万股将被动减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2475367848","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475367848?lang=zh_cn&edition=full","pubTime":"2024-10-14 21:47","pubTimestamp":1728913630,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业 发布公告，公司持股5%以上股东邱宇因与国海证券股份有限公司开展质押式证券回购业务相关债务逾期，国海证券拟依据广西壮族自治区南宁市青秀区人民法院出具的《协助执行通知书》，将通过集中竞价方式继续处置邱宇持有的755.40万股公司股份。本次减持计划自本公告披露之日起15个交易日后的3个月内进行，且任意连续90个自然日内通过集中竞价交易减持股份的总数不超过公司股份总数的1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1193821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0070","BK0239","300006"],"gpt_icon":0},{"id":"2475620353","title":"莱美药业：股东所持部分股份被动减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2475620353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475620353?lang=zh_cn&edition=full","pubTime":"2024-10-14 21:40","pubTimestamp":1728913247,"startTime":"0","endTime":"0","summary":"莱美药业公告，持股5%以上股东邱宇因与国海证券开展质押式证券回购业务相关债务逾期，国海证券拟依据广西壮族自治区南宁市青秀区人民法院出具的《协助执行通知书》，将通过集中竞价方式继续处置邱宇持有的755.40万股公司股份。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101400031556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300006"],"gpt_icon":0},{"id":"2471835875","title":"莱美药业：头孢泊肟酯干混悬剂获药品补充申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2471835875","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471835875?lang=zh_cn&edition=full","pubTime":"2024-09-30 16:55","pubTimestamp":1727686547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","BK0070","300006"],"gpt_icon":0},{"id":"2469572135","title":"莱美药业（300006）9月20日主力资金净卖出514.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2469572135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469572135?lang=zh_cn&edition=full","pubTime":"2024-09-23 09:32","pubTimestamp":1727055178,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月20日收盘，莱美药业报收于2.76元，下跌2.82%，换手率3.24%，成交量34.22万手，成交额9444.6万元。9月20日的资金流向数据方面，主力资金净流出514.1万元，占总成交额5.44%，游资资金净流入146.08万元，占总成交额1.55%，散户资金净流入368.02万元，占总成交额3.9%。近5日资金流向一览见下表：莱美药业融资融券信息显示，融资方面，当日融资买入779.71万元，融资偿还577.8万元，融资净买入201.92万元。莱美药业主营业务：医药制造。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092300002129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0070","BK0239"],"gpt_icon":0},{"id":"2463235023","title":"莱美药业最新公告：纳米炭铁混悬注射液获II期临床试验伦理批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2463235023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463235023?lang=zh_cn&edition=full","pubTime":"2024-08-29 19:00","pubTimestamp":1724929214,"startTime":"0","endTime":"0","summary":"莱美药业公告，公司控股子公司瀛瑞医药自主研发的“纳米炭铁混悬注射液”近期在四川大学华西医院通过伦理审查并收到II期临床试验批件，正式进入II期临床试验阶段。纳米炭铁是一种新机理抗癌药物，与相关化疗药物联合应用，预期在充分发挥各自抗癌优势的情况下使毒副作用保持在可以控制的范围内，进一步提高联合治疗癌症的疗效。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082900035965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0070","03347","300006","BK1141","BK0239","BK1576"],"gpt_icon":0},{"id":"2462693200","title":"莱美药业（300006）2024年中报简析：净利润增102.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462693200","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462693200?lang=zh_cn&edition=full","pubTime":"2024-08-25 06:11","pubTimestamp":1724537496,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期莱美药业发布2024年中报。根据财报显示，莱美药业净利润增102.46%。截至本报告期末，公司营业总收入3.82亿元，同比下降15.89%，归母净利润132.82万元，同比上升102.46%。按单季度数据看，第二季度营业总收入2.01亿元，同比下降11.7%，第二季度归母净利润590.35万元，同比上升111.71%。所得税费用变动幅度为329.86%,原因:本报告期利润总额同比大幅增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082500000786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006"],"gpt_icon":0},{"id":"2461068271","title":"莱美药业(300006)7月10日股东户数3.14万户，较上期减少0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461068271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461068271?lang=zh_cn&edition=full","pubTime":"2024-08-24 17:04","pubTimestamp":1724490251,"startTime":"0","endTime":"0","summary":"证券之星消息，近日莱美药业披露，截至2024年7月10日公司股东户数为3.14万户，较6月30日减少224.0户，减幅为0.71%。在化学制药行业个股中，莱美药业股东户数低于行业平均水平，截至7月10日，化学制药行业平均股东户数为3.23万户。从股价来看，2024年6月30日至2024年7月10日，莱美药业区间跌幅为1.28%，在此期间股东户数减少224.0户，减幅为0.71%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400009697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300006","BK0070"],"gpt_icon":0},{"id":"2461597975","title":"莱美药业(300006.SZ)发布上半年业绩，净利润132.82万元，扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2461597975","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461597975?lang=zh_cn&edition=full","pubTime":"2024-08-23 22:02","pubTimestamp":1724421770,"startTime":"0","endTime":"0","summary":"莱美药业(300006.SZ)发布2024年半年度报告，公司营业收入3.82亿元，...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/24.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/24.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300006"],"gpt_icon":0},{"id":"2461559594","title":"莱美药业最新公告：2024年上半年净利润132.82万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461559594","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461559594?lang=zh_cn&edition=full","pubTime":"2024-08-23 20:39","pubTimestamp":1724416782,"startTime":"0","endTime":"0","summary":"莱美药业2024年半年报显示，公司上半年实现营业收入3.82亿元，同比下降15.89%；归属于上市公司股东的净利润为132.82万元，上年同期为-5405.69万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300045957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006"],"gpt_icon":0},{"id":"2457333892","title":"知识产权保护概念盘中拉升，莱美药业涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457333892","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457333892?lang=zh_cn&edition=full","pubTime":"2024-08-08 10:34","pubTimestamp":1723084478,"startTime":"0","endTime":"0","summary":"08月08日，知识产权保护概念盘中拉升，截至10点34分，知识产权保护概念整体指数上涨0.55%，报895.230点。从个股上来看，该概念的成分股中，莱美药业涨5.14%，祥源文旅、华媒控股、安妮股份涨幅居前。从资金上来看，截止发稿，知识产权保护概念主力净流入为-2.46亿，其中祥源文旅受到资金热捧，主力净流入380.20万；拉长时间线来看，该板块近20日主力资金净流入-26.01亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808103438aefdd532&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808103438aefdd532&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0083","BK0012","BK0228","BK0102","BK0028","BK0098","BK0004","BK0211","BK0095","600576","300006","BK0149","BK0239","BK0070"],"gpt_icon":0},{"id":"2456408698","title":"莱美药业最新公告：公司及子公司诉讼事项二审终审判决结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2456408698","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456408698?lang=zh_cn&edition=full","pubTime":"2024-08-02 18:11","pubTimestamp":1722593483,"startTime":"0","endTime":"0","summary":"莱美药业公告，公司及子公司莱美医药与海悦药业因《他达拉非片中国区授权协议》纠纷案，近日收到长春市中院二审终审判决。判决结果显示，莱美医药需支付海悦药业销售款21,648,313元，公司对莱美医药的支付义务承担连带赔偿责任。经财务初步测算，本次诉讼预计影响公司本期利润总额的金额约为2969万元。公司将决定是否就二审判决申请再审，并及时履行信息披露义务。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080200039512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300006","BK0070"],"gpt_icon":0},{"id":"2453807081","title":"莱美药业：公司纳米炭混悬注射液出海工作正在稳步推进中，将力争按原定计划完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2453807081","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453807081?lang=zh_cn&edition=full","pubTime":"2024-07-23 18:01","pubTimestamp":1721728880,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业07月23日在投资者关系平台上答复投资者关心的问题。目前公司暂无上述相关计划，您的建议我们将予以转达。公司纳米炭混悬注射液出海工作正在稳步推进中，将力争按原定计划完成。目前公司控股子公司瀛瑞医药纳米炭铁临床一期工作正在稳步推进过程中，公司将根据具体临床进展情况按照交易所相关规则履行相应公告义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300034687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0070","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-10-30","address":"重庆市南岸区玉马路99号","stockEarnings":[{"period":"1week","weight":-0.0557},{"period":"1month","weight":0.145},{"period":"3month","weight":0.8926},{"period":"6month","weight":0.6655},{"period":"1year","weight":0.0577},{"period":"ytd","weight":0.2312}],"companyName":"重庆莱美药业股份有限公司","boardCode":"AI0027","perCapita":"32534股","boardName":"医药制造业","registeredCapital":"105591万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":"　　重庆莱美药业股份有限公司的主要业务为医药制造，公司产品品种丰富，结构合理，公司主要产品为化药，涵盖特色专科类（主要包括抗肿瘤药、消化系统药、肠外营养药）、抗感染类等。公司重点品种纳米炭混悬注射液(卡纳琳)，系首款获得CFDA批准的淋巴示踪剂，卡纳琳连续四年获得“中国化学制药行业原研药,专利药优秀产品品牌”,连续两年获得“中国化学制药行业其他各科用药优秀产品品牌”,获得“制造业单项冠军产品(2019-2021年)”,“2021年中国产学研合作创新与促进奖”等多项荣誉称号。","serverTime":1732338150460,"listedPrice":16.5,"stockholders":"32452人(较上一季度减少5.84%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"莱美药业,300006,莱美药业股票,莱美药业股票老虎,莱美药业股票老虎国际,莱美药业行情,莱美药业股票行情,莱美药业股价,莱美药业股市,莱美药业股票价格,莱美药业股票交易,莱美药业股票购买,莱美药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}